Skip to content ↓

In the Media

Displaying 15 news clips on page 165

WBUR

Artist Alison Nguyen’s exhibition, “History as Hypnosis” - a video installation that “surfaces themes of alienation and assimilation through three narratives” - opens this weekend at the MIT List Visual Arts Center, reports Jenn Stanley for WBUR. “Nguyen’s work explores digital media’s psychological effects on the public,” writes Stanley, “reflecting on how images are produced, circulated and consumed in mainstream U.S. culture.”

Popular Science

Popular Science reporter Andrew Paul writes that MIT engineers have developed a new chip for smart phones that blocks unwanted signals, which could “greatly reduce production costs, make devices smaller and more efficient, and potentially even improve battery life.” Graduate student Soroush Araei explains that “our research can make your devices work better with fewer dropped calls or poor connections caused by interference from other devices.”

Fast Company

Fast Company reporter Amelia Hemphill spotlights the work of Alicia Chong Rodriguez SM ’17, SM ’18, and her startup Bloomer Tech, which is “dedicated to transforming women’s underwear into a healthcare device.” “Our big goal is to generate digital biomarkers,” says Chong Rodriguez. “Digital biomarkers work more like a video, so it will definitely allow a more personalized care from the physician to their patient.”

Bloomberg

Bloomberg reporter Tanaz Meghjani writes that MIT researchers created a new system to 3D print a customized replica of the human heart, which could help improve replacement valve procedures. The new system “mimics blood flow and pressure in individual diseased hearts, suggesting a way to predict the effects of various replacements and select the best fit, avoiding potential leakage and failure,” Meghjani writes.

WBUR

MIT engineers have developed a new technique for 3D printing a soft, flexible, custom-designed replica of a patient’s heart, report Gabrielle Emanuel and Amy Sokolow for WBUR. The goal of the research is to “provide realistic models so that doctors, researchers and medical device manufacturers can use them in testing therapies for different types of heart disease,” Emanuel and Sokolow explain.

The Boston Globe

Aera Therapeutics, founded by Prof. Feng Zhang, is working to “debut a type of protein nanoparticle that it believes can be used to ferry all sorts of genetic medicines around the body,” reports Lisa Jarvis for Bloomberg.

VICE

Graduate student Ziv Epstein speaks with Vice reporter Rachel Cheung about the legal implications of the development and use of AI tools being used to create art. “We need more both technical and social research, understanding how these things work, how people feel about them, and then we can make those decisions based on good science,” Epstein said. “Because right now, we’re just really at the brink of the beginning.”

VICE

Writing for The Boston Globe, Prof. Erin Kelly shares her research on the impact of remote work. “The challenge is setting boundaries and feeling it’s acceptable to set them, and that requires deliberate company policies,” writes Kelly.

Mashable

MIT researchers have constructed a mini city to test to safely test algorithms designed for autonomous vehicles, reports Mashable. “The idea of the mini city is that we have lots of cars going at the same time and we can actually test out new algorithms in a safe environment,” says graduate student Noam Buckman.

Fortune

Writing for Fortune, Prof. Elazer R. Edelman and Mike Mussallem of Edwards Lifesciences write that the backlog of deferred medical treatments caused by the Covid-19 pandemic and resulting long-term health consequences could impact public health for years. Edelman and Mussallem emphasize that “it is incumbent upon us to identify timely real-world evidence to elucidate the effects of policy changes so they can be adaptive and agile enough to provide access to critical interventions and procedures.”

The New Yorker

Prof. M. Taylor Fravel, director of the MIT Security Studies Program, speaks with New Yorker reporter Isaac Chotiner about China’s military strategy and the future of U.S.-China relations. “In the last five years, China, with a much more modern military, has many more options that it can draw from when it’s thinking about how to advance its interests,” says Fravel. “It can use displays of force to much greater effect than before.”

Cambridge Day

After almost 50 years, the MIT Juggling Club, which was founded in 1975 and then merged with a unicycle club, is the oldest drop-in juggling club in continuous operation and still welcomes any aspiring jugglers to come toss a ball into the air, reports Stacy Kess for Cambridge Day. Through the years the club has “attracted a cross-section of humanity: young, old, students, professors, people who changed the course of the world, artists, writers, performers and the juggling-curious,” writes Kess. 

The Wall Street Journal

A new study co-authored by Prof. S.P. Kothari “analyzes the stock returns of thousands of companies from 1988-2020, comparing those that repurchased shares against firms that didn’t, adjusting for their size and other factors,” reports Jason Zweig for The Wall Street Journal. “We don’t see massive misuse as some people allege,” says Kothari. “This isn’t a rigged game where CEOs are lining their pockets.”

Politico

Researchers at MIT and elsewhere are analyzing patients’ speech patterns to see if they can detect Lou Gehrig’s disease in its early stages, reports Ben Leonard, Ruth Reader, Carmen Paun and Erin Schumaker for Politico. “Catching it early and beginning treatment can improve patients’ quality of life and delay symptom onset,” they write.  

The Boston Globe

Prof. Feng Zhang founded Aera Therapeutics, a startup working to deliver curative genetic medicine to hard-to-reach parts of the body, reports Ryan Cross for The Boston Globe. “If Aera’s approach works in people, it could broaden the reach of genetic therapies, which currently have limited clinical applications – partly because there aren’t enough methods for getting those medicines to hone in on the right cells,” writes Cross.